Nicoletta Sacchi

Nicoletta Sacchi

Auto-generated profile, based on publicly available information

Nicoletta Sacchi

Ente Ospedaliero Ospedali Galliera , Genoa 16128

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Human Immunology
Verified
Journal Article
Closed access
LCLisa E. Creary
Lisa E. Creary
NSNicoletta Sacchi
Nicoletta Sacchi
MMMichela Mazzocco
Michela Mazzocco
GMGerald P. Morris
Gerald P. Morris
GMGonzalo Montero-Martin
Gonzalo Montero-Martin
MFMarcelo A. Fernández-Viña
Marcelo A. Fernández-Viña

17 June 2019 in HLA
Verified
Journal Article
Open access
PDF file
NSNicoletta Sacchi
Nicoletta Sacchi
MCMauro Castagnetta
Mauro Castagnetta
VMValeria Miotti
Valeria Miotti
LGLucia Garbarino
Lucia Garbarino
AGAnnamaria Gallina
Annamaria Gallina
HLA genes are highly polymorphic and structurally complex. They are located in the major histocompatibility complex (MHC) on chromosome 6, and the frequency of alleles and haplotypes varies widely among human populations.In this paper, we calculated the allele and haplotype frequencies using the HLA data of more than 120 000 Italian unrelated bone marrow donors enrolled in the national registry (IBMDR) and typed them with a high‐resolution (HR) method for the HLA‐A, ‐B, ‐C and ‐DRB1 alleles. The allele frequency data were obtained by manual counting; haplotype frequencies were calculated using the expectation maximisation (EM) algorithm. The total numbers of observed alleles were 226 for HLA‐A, 343 for HLA‐B, 201 for HLA‐C and 210 for HLA‐DRB1, which account for 5.4%, 6.7%, 5.2% and 8.5%, respectively, of each locus allele (IPD‐IMGT/HLA Database Release 3.32, April 2018). The three most frequent Italian haplotypes were HLA‐A*01:01~B*08:01~C*07:01~DRB1*03:01 (2.5%), A*02:01~B*18:01~C*07:01~DRB1*11:04 (1.1%) and A*30:01~B*13:02~C*06:02~DRB1*07:01 (1.1%). Moreover, for a relevant subset of the examined population (>100 000 individuals), the birthplace was available, and thus, we grouped the frequency data based on the corresponding Italian geographic areas, describing the HLA specificity of the Italian regional populations. The haplotype frequencies were also compared between national and regional data, and we observed remarkable differences in the regional haplotype frequencies, particularly in Sardinia. This study represents a valid tool to identify a more efficient haematopoietic stem cell unrelated donor recruitment and selection strategy, as well as for population genetic and HLA‐disease association fields.

13 January 2022 in HLA
Verified
Journal Article
Open access
PDF file
RCRoberto Crocchiolo
Roberto Crocchiolo
AGAnna Maria Gallina
Anna Maria Gallina
APArianna Pani
Arianna Pani
DCDaniela Campisi
Daniela Campisi
VCValeria Cento
Valeria Cento
SRSilvano Rossini
Silvano Rossini
The polymorphism of the HLA system has been extensively studied in COVID‐19 infection, however there are no data about the role of HLA on vaccine response. We report here the HLA‐A, ‐B, ‐C, and DRB1 allelic frequencies of n = 111 individuals after BNT162b2 mRNA vaccine, selected on the basis of lower antibody levels (<5% percentile) after the second dose among a total of n = 2569 vaccinees, and compare them with the frequencies of a reference population. We found that differences in the frequencies of the alleles HLA‐A*03:01, A*33:03, B*58:01 and at least one haplotype (HLA‐A*24:02~C*07:01~B*18:01~DRB1*11:04) are associated with a weaker antibody response after vaccination, together with the age of vaccinees. Our results might suggest a role played by some HLA alleles or haplotypes in antibody production after the BNT162b2 mRNA vaccine, giving insights into the tracking of potentially susceptible individuals across populations. Further studies are needed to better define our exploratory findings and dissect the role of HLA polymorphism on response to anti‐COVID‐19 vaccines.

1 January 1996 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
NSN. Sacchi
N. Sacchi
IMI. Magnani
I. Magnani
AFA.M. Fuhrman-Conti
A.M. Fuhrman-Conti
SMS.P. Monard
S.P. Monard
MDM. Darfler
M. Darfler
Centromere activation, an important mechanism in karyotype evolution, is occasionally observed in some human chromosome rearrangements. We report a possible occurrence of centromere activation in a marker chromosome containing an atypical centromere associated with an inverted duplication of the region 14q32→qter. The marker chromosome’s reduced centromere lacks both the α and β satellite sequences usually found at normal centromeres. In an attempt to identify the centromeric sequences, the marker chromosome was flow-sorted and amplified by a degenerate oligonucleotide primer polymerase chain reaction. Reverse chromosome painting experiments showed that the marker chromosome contains sequences that are unique to the distal region of chromosome 14, as well as a low copy number of (centromeric) sequences that are also highly represented in the centromeres of chromosomes 18 and 19. These data suggest the activation of a novel centromere in the 14q32→qter region, very likely consequent to the duplication of the region itself.

9 April 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MJMonique M. Jöris
Monique M. Jöris
ASAlexander H. Schmidt
Alexander H. Schmidt
SBStefanie N. Bernas
Stefanie N. Bernas
JFJay Feinberg
Jay Feinberg
NSNicoletta Sacchi
Nicoletta Sacchi
LFLydia Foeken
Lydia Foeken

14 April 2025 in Blood Advances
Verified
Journal Article
Open access
ARAnna Maria Raiola
Anna Maria Raiola
BBBENEDETTO BRUNO
BENEDETTO BRUNO
ARAntonio Maria Risitano
Antonio Maria Risitano
FMFederico Mosna
Federico Mosna
ICIrene Maria Cavattoni
Irene Maria Cavattoni
FBFrancesca Bonifazi
Francesca Bonifazi
Posttransplant high-dose cyclophosphamide (PTCy) is effective in overcoming the negative impact of HLA disparity in the haploidentical setting. In light of these results, we investigated the efficacy of PTCy, in improving clinical outcomes of hematopoietic stem cell transplantation (HSCT) from a mismatched unrelated donor (MMUD) in patients with acute myeloid malignancies by reducing the incidence and severity of acute graft-versus-host disease (aGVHD). A prospective, single-arm, phase 2 study (PHYLOS) was conducted by the Gruppo Italiano Trapianto di Midollo Osseo. The ethical committees of the participating centers approved the study (EURODRACT 2017-003530-85). A total of 77 consecutive patients (acute myeloid leukemia: 64; myelodysplastic syndrome: 13) were enrolled at 26 Italian transplant centers (January 2020-November 2022). Median age of the patients was 53 (range, 19-65) years. The 100-day cumulative incidence of grades 2 to 4 aGVHD was 18.2% (95% CI, 10.6-27.6) and of grades 3 to 4 was 6.5% (95% CI, 3.1-15.1). Seventy-one patients (92%) had full-donor chimerism with complete neutrophil engraftment by day +30. One-year cumulative incidence of chronic GVHD was 13.4% (95% CI, 6.9-22.1). One-year cumulative incidence of nonrelapse mortality was 9.1% (95% CI, 4.0-16.9), and the relapse rate was 23.8% (95% CI, 14.9-33.9). One-year overall survival and graft relapse-free survival were 78.6% (95% CI, 67.4-86.3) and 55.3% (95% CI, 43.4-65.7), respectively. Our study in a homogeneous patient cohort suggests that PTCy leads to a low rate of aGVHD and improves clinical outcomes of HSCT from MMUD. This trial was registered at www.clinicaltrials.gov as #NCT03270748.